Inclusion complexes of tadalafil with natural and chemically modified β-cyclodextrins. I: Preparation and in-vitro evaluation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 3, 2008, Pages 819-827

  Badr Eldin, Shaimaa M ^a   Elkheshen, Seham A ^a   Ghorab, Mahmoud M ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Chemically modified cyclodextrin; Cyclodextrin; In vitro dissolution; Inclusion complexes; Physicochemical characterization; Tadalafil

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; HEPTAKIS(2,6 O DIMETHYL) BETA CYCLODEXTRIN; TADALAFIL;

ARTICLE; CHEMICAL MODIFICATION; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; EVALUATION; FREEZE DRYING; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; SOLID STATE; TABLET FORMULATION; ULTRAVIOLET SPECTROSCOPY; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBOLINES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DRUG COMPOUNDING; EXCIPIENTS; FREEZE DRYING; KINETICS; PHOSPHODIESTERASE INHIBITORS; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 54949135704     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.06.024     Document Type: Article

References (38)

1. Hussar D.A. New drugs of 2003. J. Am. Pharm. Assoc. 44 (2004) 168-206
2. Porst H., Padma-Nathan H., Giuliano F., Anglin G., Varanese L., and Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 62 (2003) 121-126
3. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am. J. Cardiol. 92 (2003) 19M-25M
4. .
5. Fernandes C.M., Teresa V.M., and Veiga F.J. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur. J. Pharm. Sci. 15 (2002) 79-88
6. Nagarsenker M.S., and Joshi M.S. Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage. Drug Dev. Ind. Pharm. 31 (2005) 169-178
7. Rajendrakumar K., Madhusudan S., and Pralhad T. Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in rat. Eur. J. Pharm. Biopharm. 60 (2005) 39-46
8. Jun S.W., Kim M.S., Kim J.S., Park H.J., Lee S., Woo J.S., and Hwang S.J. Preparation and characterization of simvastatin/hydroxypropyl-β-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 66 (2007) 413-421
9. Rajewski R.A., and Stella V.J. Pharmaceutical applications of cyclodextrins. 2: In vivo drug delivery. J. Pharm. Sci. 85 (1996) 1142-1169
10. Connors K.A., and Mollica J.A. Theoretical analysis of comparative studies of complex formation. J. Pharm. Sci. 55 (1966) 772-780
11. Higuchi T., and Connors K.A. Phase solubility techniques. In: Reilly C.N. (Ed). Advances in Analytical and Chemistry Instrumentation vol. 4 (1965), Wiley Interscience, New York 117-212
12. Loftsson T., Masson M., and Sigurjonsdottir J.F. Methods to enhance the complexation efficiency of cyclodextrin. STP Pharma Sci. 9 (1999) 237-242
13. Habib M.J., Phan M.T., and Owusu-Ababio G. Dissolution profiles of flurbiprofen in phospholipids solid dispersions. Drug Dev. Ind. Pharm. 24 (1998) 1077-1082
14. Khan K.A., and Rhodes C.T. Effect of compaction pressure on the dissolution efficiency of direct compression systems. Pharm. Acta Helv. 47 (1972) 594-607
15. Ventura C.A., Giannone I., Musumeci T., Pignatello R., Ragni L., Landolfi C., Milanese C., Paolino D., and Puglisi G. Physico-chemical characterization of disoxaril-dimethyl-β-cyclodextrin inclusion complex and in vitro permeation studies. Eur. J. Med. Chem. 41 (2006) 233-240
16. Crupi V., Ficarra R., Guardo M., Majolino D., Stancanelli R., and Venuti V. UV-vis and FTIR-ATR spectroscopic techniques to study the inclusion complexes of genistein with β-cyclodextrins. J. Pharm. Biomed. Anal. 4 (2007) 110-117
17. Loftsson T., Masson M., and Brewster M.E. Self association of cyclodextrin and cyclodextrin complexes. J. Pharm. Sci. 93 (2004) 1091-1099
18. Arima H., Yunomae K., Miyake K., Irie T., Hirayama F., and Uekama K. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J. Pharm. Sci. 90 (2001) 690-701
19. Loftsson T., Magnúsdóttir A., Másson M., and Sigurjónsdóttir J.F. Self association and cyclodextrin solubilization of drugs. J. Pharm. Sci. 91 (2002) 2307-2316
20. Ahmed M.O. Comparison of impact of the different hydrophilic carriers on the properties of piperazine-containing drug. Eur. J. Pharm. Biopharm. 51 (2001) 221-226
21. Mura P., Adragna E., Rabasco A.M., Moyano J.R., Pérez-Marti{dotless}̀nez J.I., Arias M.J., and Ginés J.M. Effects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam-cyclodextrin systems. Drug Dev. Ind. Pharm. 25 (1999) 279-287
22. Liu J., Qui L., Gao J., and Jin Y. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 312 (2006) 137-143
23. Bayomi M.A., Abanumany K.A., and Al-Angary A.A. Effect of inclusion complexation with cyclodextrins on photostability of nifedipine in solid state. Int. J. Pharm. 243 (2002) 107-117
24. Manosroi J., Apriyani M.G., Foe K., and Manosroi A. Enhancement of the release of azaleic acid through the synthetic membranes by inclusion complex formation with hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 293 (2005) 235-240
25. Ribeiro L.S.S., Ferreira D.C., and Veiga F.J.B. Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur. J. Pharm. Sci. 20 (2003) 253-266
26. Veiga M.D., Di{dotless}̀az P.J., and Ahsan F. Interactions of griseofulvin with cyclodextrins in solid binary systems. J. Pharm. Sci. 87 (1998) 891-900
27. Williams R.O., Mahaguna V., and Sriwongjanya M. Characterization of a inclusion complex of cholesterol and hydroxypropyl-β-cyclodextrin. Eur. J. Pharm. Biopharm. 46 (1998) 355-360
28. Redenti E., Peveri T., Zanol M., Ventura P., Gnappi G., and Montenero A. A study on the differentiation between amorphous piroxicam:β-cyclodextrin complex and a mixture of the two amorphous components. Int. J. Pharm. 129 (1996) 289-294
29. Beraldo H., Sinisterra R.D., Teixeira L.R., Vieira R.P., and Doretto M.C. An effective anticonvulsant prepared following a host-guest strategy that uses hydroxypropyl-β-cyclodextrin and benzaldehyde semicarbazone. Biochem. Biophys. Res. Commun. 296 (2002) 241-246
30. Ficarra R., Ficarra P., Di Bella M.R., Raneri D., Tommasini S., Calabrò M.L., Villari A., and Coppolino S. Study on the inclusion complex of atenolol with β-cyclodextrin. J. Pharm. Biomed. Anal. 23 (2000) 231-236
31. Moyano J.R., Ginés J.M., Arias M.J., and Rabasco A.M. Study of the dissolution characteristics of oxazepam via complexation with β-cyclodextrin. Int. J. Pharm. 114 (1995) 95-102
32. Dollo G., Corre P., Chollet M., Chevanne F., Bertault M., Burgot J., and Verge R. Improvement in solubility and dissolution rate of 1,2-dithiole-3-thiones upon complexation with β-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives. J. Pharm. Sci. 88 (1999) 889-895
33. Betageri G.V., and Makarla K.R. Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. Int. J. Pharm. 126 (1995) 155-160
34. Cirri M., Rangoni C., Maestrelli F., Corti G., and Mura P. Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes. Drug Dev. Ind. Pharm. 31 (2005) 697-707
35. Johnson J.L.H., He Y., Jain A., and Yalkowsky S.H. Improving cyclodextrin complexation of a new antihepatitis drug with glacial acetic acid. AAPS PharmSciTech 7 (2006) E1-E6 article 18
36. Loftsson T., Sigurdsson H.H., Másson M., and Schipper N. Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs. Pharmazie 59 (2004) 25-29
37. Elkheshen S.A., Ahmed S.M., and Al-Quadeib B.T. Inclusion complexes of piroxicam with β-cyclodextrin derivatives in comparison with the natural β-cyclodextrin: in-vitro and in-vivo drug availability. Pharm. Ind. 64 (2002) 708-715
38. Gould S., and Scott R.C. 2-Hydroxypropyl-β-cyclodextrin: a toxicology review. Food Chem. Toxicol. 43 (2005) 1451-1459